{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T06:34:20Z","timestamp":1782282860546,"version":"3.54.5"},"reference-count":38,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Eur J Hosp Pharm"],"accepted":{"date-parts":[[2025,3,24]]},"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1136\/ejhpharm-2024-004450","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T13:20:17Z","timestamp":1744204817000},"page":"126-136","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["The FUSION Study: compatibility of antibiotics with commonly used medication infusions in a paediatric intensive care unit"],"prefix":"10.1136","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1910-1069","authenticated-orcid":false,"given":"Quyen","family":"Tu","sequence":"first","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"},{"name":"Critical Care, Queensland Children\u2019s Hospital Paediatric Intensive Care Unit, South Brisbane, Queensland, Australia"},{"name":"Department of Pharmacy, Children\u2019s Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayoung","family":"Won","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4061-2063","authenticated-orcid":false,"given":"Fekade Bruck","family":"Sime","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"},{"name":"Centre for Translational Anti-Infective Pharmacodynamics, School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sainath","family":"Raman","sequence":"additional","affiliation":[{"name":"Critical Care, Queensland Children\u2019s Hospital Paediatric Intensive Care Unit, South Brisbane, Queensland, Australia"},{"name":"Children\u2019s Intensive Care Research Program (ChIRP), Child Health Research Centre (CHRC), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menino Osbert","family":"Cotta","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C","family":"Wallis","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5733-937X","authenticated-orcid":false,"given":"Dusan","family":"Marjanovic","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Stacey","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Children\u2019s Health Queensland Hospital and Health Service, South Brisbane, Queensland, Australia"},{"name":"School of Pharmacy, The University of Queensland, Brisbane, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luregn","family":"Schlapbach","sequence":"additional","affiliation":[{"name":"Child Health Research Centre (CHRC), The University of Queensland, Brisbane, Queensland, Australia"},{"name":"Department of Pediatric and Neonatal Intensive Care, University Children\u2019s Hospital Z\u00fcrich, Z\u00fcrich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason A","family":"Roberts","sequence":"additional","affiliation":[{"name":"University of Queensland Centre for Clinical Research (UQCCR), Faculty of Medicine, The University of Queensland, Brisbane, Queensland, Australia"},{"name":"Herston Infectious Diseases Institute (HeIDI), Metro North Health, Brisbane, Queensland, Australia"},{"name":"Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Woman\u2019s Hospital Health Service District, Brisbane, Queensland, Australia"},{"name":"UR UM 103, University of Montpellier, Division of Anesthesia Critical Care and Emergency and Pain Medicine, Nimes University Hospital, Nimes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"2026022302200637000_33.2.126.1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008780126781"},{"key":"2026022302200637000_33.2.126.2","doi-asserted-by":"crossref","DOI":"10.1186\/s13054-022-03957-7","article-title":"Pain and sedation management and monitoring in pediatric intensive care units across Europe: an ESPNIC survey","volume":"26","author":"Daverio","year":"2022","journal-title":"Crit Care"},{"key":"2026022302200637000_33.2.126.3","doi-asserted-by":"publisher","DOI":"10.1007\/s00134-019-05877-7"},{"key":"2026022302200637000_33.2.126.4","doi-asserted-by":"crossref","first-page":"102293","DOI":"10.1016\/j.eclinm.2023.102293","article-title":"Extended infusion of \u03b2-lactams significantly reduces mortality and enhances microbiological eradication in paediatric patients: a systematic review and meta-analysis","volume":"65","author":"Budai","year":"2023","journal-title":"EClinicalMedicine"},{"key":"2026022302200637000_33.2.126.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.9803"},{"key":"2026022302200637000_33.2.126.6","first-page":"67","article-title":"Difficult intravenous access in a paediatric intensive care unit","volume":"33","author":"de la Vieja-Soriano","year":"2022","journal-title":"Enferm Intensiva (Engl Ed)"},{"key":"2026022302200637000_33.2.126.7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.medine.2018.08.008","article-title":"Compatibility of drugs administered as Y-site infusion in intensive care units: A systematic review","volume":"44","author":"Castells Lao","year":"2020","journal-title":"Medicina Intensiva (English Edition)"},{"key":"2026022302200637000_33.2.126.8","first-page":"173","article-title":"Clinical implications of intravenous drug incompatibilities in critically ill patients","volume":"38","author":"Benlabed","year":"2019","journal-title":"Anaesth Crit Care Pain Med"},{"key":"2026022302200637000_33.2.126.9","doi-asserted-by":"publisher","DOI":"10.1515\/pthp-2016-0004"},{"key":"2026022302200637000_33.2.126.10","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2842"},{"key":"2026022302200637000_33.2.126.11","unstructured":"Australian Injectable Drugs Handbook. 8th edn. Society of Hospital Pharmacists of Australia, 2023."},{"key":"2026022302200637000_33.2.126.12","unstructured":"Children\u2019s Intensive Care Drug Directory (CIDD) 1st ed. Children\u2019s Health Queensland Hospital and Health Service, 2022. Available: https:\/\/qheps.health.qld.gov.au\/__data\/assets\/pdf_file\/0021\/2831115\/gdl-69000.pdf"},{"key":"2026022302200637000_33.2.126.13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/pan.14598","article-title":"Exploring a case of incompatibility in a complex regimen containing Plasma-Lyte 148 in the pediatric intensive care","volume":"33","author":"Nilsson","year":"2023","journal-title":"Paediatr Anaesth"},{"key":"2026022302200637000_33.2.126.14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s40635-018-0205-2","article-title":"Analysis of particulate exposure during continuous drug infusion in critically ill adult patients: a preliminary proof-of-concept in vitro study","volume":"6","author":"Benlabed","year":"2018","journal-title":"Intensive Care Med Exp"},{"key":"2026022302200637000_33.2.126.15","unstructured":"Santillo M , Austin P , Campbell C , et al . A standard protocol for deriving and assessment of stability. Part 1 - Aseptic preparations (small molecules). 2019. Available: https:\/\/www.sps.nhs.uk\/wp-content\/uploads\/2013\/12\/Stability-part-1-small-molecules-5th-Ed-Sept-19.pdf"},{"key":"2026022302200637000_33.2.126.16","unstructured":"European Pharmacopoeia . Chapter 2.9.19. Particulate Contamination: Sub-Visible Particles. 10th edn. Council of Europe, European Directorate for the Quality of Medicines & Healthcare, 2021:3."},{"key":"2026022302200637000_33.2.126.17","unstructured":"HIAC 9703+ Pharmaceutical Particle Counter. Beckman-Coulter. Available: https:\/\/www.mybeckman.uk\/liquid-particle-counters\/hiac-9703-plus [Accessed 25 Jul 2022]."},{"key":"2026022302200637000_33.2.126.18","doi-asserted-by":"publisher","DOI":"10.1310\/hpj5202-132"},{"key":"2026022302200637000_33.2.126.19","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2012-000112"},{"key":"2026022302200637000_33.2.126.20","unstructured":"Trissel LA . Cefotaxime compatibility with common parenteral medications 2007. 2023. Updated; 2007. Available: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowIVCompResults [Accessed 29 Jul 2023]."},{"key":"2026022302200637000_33.2.126.21","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1985.tb03411.x"},{"key":"2026022302200637000_33.2.126.22","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(91)80246-6"},{"key":"2026022302200637000_33.2.126.23","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/pan.13554","article-title":"Physico-chemical stability of Plasma-Lyte 148\u00ae and Plasma-Lyte 148\u00ae + 5% Glucose with eight common intravenous medications","volume":"29","author":"Dawson","year":"2019","journal-title":"Paediatr Anaesth"},{"key":"2026022302200637000_33.2.126.24","unstructured":"Trissel LA . Piperacillin sodium - tazobactam sodium compatibility with selected antineoplastic, anti-infective, and other drugs 2004. Micromedex, 2023. Available: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowIVCompResults [Accessed 29 Jul 2023]."},{"key":"2026022302200637000_33.2.126.25","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/10826076.2011.582909","article-title":"Chemical Stability and Compatibility Study of Vancomycin for Administration by Continuous Infusion in Intensive Care Units","volume":"34","author":"Pauwels","year":"2011","journal-title":"J Liq Chromatogr Relat Technol"},{"key":"2026022302200637000_33.2.126.26","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1177\/0018578719844168","article-title":"Compatibility of Y-Site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs","volume":"55","author":"Lessard","year":"2020","journal-title":"Hosp Pharm"},{"key":"2026022302200637000_33.2.126.27","unstructured":"Trissel LA . Morphine sulfate compatibility with selected parenteral drugs 2007. Micromedex; 2023. Available: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowIVCompResults [Accessed 29 Jul 2023]."},{"key":"2026022302200637000_33.2.126.28","unstructured":"Trissel LA . Fentanyl citrate compatibility with common parenteral medications 2007. Micromedex; 2007. Available: https:\/\/www.micromedexsolutions.com\/micromedex2\/librarian\/PFDefaultActionId\/evidencexpert.ShowIVCompResults [Accessed 29 Jul 2023]."},{"key":"2026022302200637000_33.2.126.29","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.4.550"},{"key":"2026022302200637000_33.2.126.30","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics11040458","article-title":"Stability Studies of 16 Antibiotics for Continuous Infusion in Intensive Care Units and for Performing Outpatient Parenteral Antimicrobial Therapy","volume":"11","author":"Loeuille","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2026022302200637000_33.2.126.31","article-title":"Liberal versus conservative fluid therapy in adults and children with sepsis or septic shock","volume":"12","author":"Li","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2026022302200637000_33.2.126.32","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s00228-021-03112-1","article-title":"Strategies to prevent drug incompatibility during simultaneous multi-drug infusion in intensive care units: a literature review","volume":"77","author":"N\u00e9grier","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"2026022302200637000_33.2.126.33","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122220","article-title":"Simultaneous infusion of two incompatible antibiotics: Impact of the choice of infusion device and concomitant simulated fluid volume support on the particulate load and the drug mass flow rates","volume":"627","author":"N\u00e9grier","year":"2022","journal-title":"Int J Pharm"},{"key":"2026022302200637000_33.2.126.34","doi-asserted-by":"crossref","DOI":"10.3390\/ph17091222","article-title":"Evaluation of the Impact of Infusion Set Design on the Particulate Load Induced by Vancomycin-Piperacillin\/Tazobactam Incompatibility","volume":"17","author":"N\u00e9grier","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026022302200637000_33.2.126.35","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/pbc.25442","article-title":"In vitro analysis of overall particulate contamination exposure during multidrug IV therapy: impact of infusion sets","volume":"62","author":"Perez","year":"2015","journal-title":"Pediatr Blood Cancer"},{"key":"2026022302200637000_33.2.126.36","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15082069","article-title":"Evaluation of Strategies for Reducing Vancomycin-Piperacillin\/Tazobactam Incompatibility","volume":"15","author":"Martin Mena","year":"2023","journal-title":"Pharmaceutics"},{"key":"2026022302200637000_33.2.126.37","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/jphp.12647","article-title":"Physical compatibility of total parenteral nutrition and drugs in Y-site administration to children from neonates to adolescents","volume":"69","author":"Staven","year":"2017","journal-title":"J Pharm Pharmacol"},{"key":"2026022302200637000_33.2.126.38","doi-asserted-by":"crossref","unstructured":"Sharma M , Cheung JK , Dabbara A , et al . Intravenous Admixture Compatibility for Sterile Products: Challenges and Regulatory Guidance. New York: Springer, 2013:461\u201374.","DOI":"10.1007\/978-1-4614-7978-9_17"}],"container-title":["European Journal of Hospital Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ejhpharm-2024-004450","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T10:21:07Z","timestamp":1771842067000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhp.bmj.com\/lookup\/doi\/10.1136\/ejhpharm-2024-004450"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,23]]},"published-print":{"date-parts":[[2026,3]]}},"alternative-id":["10.1136\/ejhpharm-2024-004450"],"URL":"https:\/\/doi.org\/10.1136\/ejhpharm-2024-004450","relation":{},"ISSN":["2047-9956","2047-9964"],"issn-type":[{"value":"2047-9956","type":"print"},{"value":"2047-9964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}